TCL Archive Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up December 26, 2014
TCL Archive Georgetown-Hackensack Consortium Plan Points to Rising Value of NCI Designation April 19, 2013
TCL Archive NCI Programs: BSA Approves concept For Grants Program In Statistical Modeling July 16, 1999
TCL Archive In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List December 2, 1983